La cadena de opciones muestra datos clave de las opciones de acciones de Mineralys Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Mineralys Therapeutics..

Mineralys Therapeutics (NASDAQ:MLYS) Bolsa, Cadena de Opciones

MINERALYS THERAPEUTICS INC

Mineralys Therapeutics

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Twilio sube un 18,5% tras superar expectativas de ingresos. Explora los movimientos clave del mercado previo de hoy.

Acciones de Twilio (TWLO) se disparan más de un 18%; 20 acciones que se mueven en el premercado de EE.UU.

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics Inc

Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), the media venture of President Donald Trump, has announced its expansion into Canada and Mexico. The company&#8217;s&nbsp;Truth Social platform and Truth+&nbsp;TV streaming services are now available in these countries.
What Happened: The expansion of TMTG into Canada and Mexico comes amidst a global tariff war instigated by Trump. The company&#8217;s Truth+ mobile&nbsp;and TV apps are now&nbsp;available for download in both countries, according to a recent announcement. &#8220;Truth&nbsp;Social and Truth+ are now&nbsp;fully open for business&#8221; in Canada and Mexico, stated&nbsp;Trump Media CEO Devin Nunes.
&#8220;We hope our northern and southern neighbors will enjoy a refuge from Big Tech corporations, monotonous news channels, and woke TV shows and movies,&#8221; Nunes added. 
The Truth+ mobile app is now accessible on iOS and Android devices, while the TV apps can be found on Roku, Apple, Android, and Amazon Fire TV. In addition to these, Trump Media also owns the fintech platform Truth.Fi.
The timing of this expansion coincides with Trump&#8217;s imposition of hefty&nbsp;tariffs on over 60&nbsp;countries, which has led to a global market sell-off. Interestingly, Canada and Mexico were exempted from this list due to a 25% tariff already imposed in February on all goods not covered by the U.S.-Mexico-Canada trade agreement.
SEE ALSO:&nbsp;<a href="https://benzinga.com/tech/25/04/44726879/vietnam-a-hub-for-us-tech-giants-like-apple-and-nvidia-wants-to-talk-trade-after-trump-pauses-46-tariff" target="_blank" rel="noreferrer noopener">Vietnam, A Hub For US Tech Giants Like Apple And Nvidia, Wants To Talk Trade After Trump Pauses 46% Tariff</a>
Why It Matters: The expansion of TMTG into Canada and Mexico is significant, especially against the backdrop of the ongoing global tariff war. This move could be seen as a strategic one, considering that these two countries were exempted from the tariff impositions on &#8216;Liberation Day&#8217; because in February, Trump imposed a 25% tariff on imports from Mexico and Canada, particularly targeting goods not included in the United States-Mexico-Canada Agreement (USMCA)
Furthermore, this development comes on the heels of a surge in Trump Media&#8217;s stock. The company&#8217;s <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44724530/trump-media-stock-soars-hours-after-president-says-its-a-great-time-to-buy-what-you-need-to-know">shares soared</a> following President Trump&#8217;s announcement of a 90-day pause on reciprocal tariffs. ​On Wednesday afternoon, President Trump used his social media platform, Truth Social make this significant announcement.<a href="https://www.theaustralian.com.au/world/china-threatens-to-hit-back-again-as-trumps-new-tariff-hit-hours-away/news-story/49953d38032694d157c3bbd4d875640e?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener"></a>
The availability of Truth+ mobile and TV apps in Canada and Mexico could potentially boost the company&#8217;s user base and revenue. This momentum could further propel the company&#8217;s growth in the new markets.
DJT Price Action:&nbsp;<a href="http://benzinga.com/quote/djt?tblci=GiD1tFFNH-r-bulyXzVS-mm-BVNR3nb6Ojb3DSX9l1ZrFSCN1Vcox-6pnqzj16QvMO-ISg" target="_blank" rel="noreferrer noopener">Trump Media shares</a>&nbsp;surged nearly 22% to close at $20.27 on Wednesday, per&nbsp;<a href="http://pro.benzinga.com/?tblci=GiD1tFFNH-r-bulyXzVS-mm-BVNR3nb6Ojb3DSX9l1ZrFSCN1Vcox-6pnqzj16QvMO-ISg" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The stock declined more than 40% over the past year.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/44731819/why-the-bitcoin-bull-market-is-back-on-at-93000-glassnode" target="_blank" rel="noreferrer noopener">Why The Bitcoin Bull Market Is Back On At $93,000: Glassnode &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Media (DJT) Expands Into Canada And Mexico Amid Global Tariff Tensions

JMP Securities analyst Andrew Boone reiterates Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) from Market Perform to Market Perform.

Reiteration

Analyst Ratings

GOOGL

JMP Securities Reiterates Market Perform on Alphabetto Market Perform

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) with a Buy and raises the price target from $45 to $47.

Price Target

TVTX

Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $47

ReShape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) on Wednesday signed an agreement with Haifa, Israel-based Motion Informatics to exclusively import and distribute their neuromuscular rehabilitation <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">devices in the U.S</a>.
The flagship product, the Stimel-03, was showcased at the American Occupational Therapy Association 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44722857/reshape-lifesciences-partners-with-motion-informatics-to-bring-ai-driven-neurorehabilitation-techn" rel="noreferrer noopener">Annual Conference and Expo</a>.
&#8220;The signing of this agreement with Motion Informatics marks a significant milestone for ReShape as we expand and diversify into rehabilitation technology,&#8221; ReShape CEO Paul F. Hickey said.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44721380/redwire-joins-ispace-us-in-pursuit-of-nasas-26b-lunar-economy-mission" rel="noreferrer noopener">Redwire Joins ispace Tech In Pursuit Of NASA&#8217;s $2.6 Billion Lunar Economy Mission</a>
Stimel-03 is FDA-cleared and commercially available. It&#8217;s a single, patient-responsive platform that helps patients recover from stroke, injury, or surgery.
&#8220;This partnership accelerates Motion Informatics&#8217; U.S. market strategy by combining ReShape Lifesciences&#8217; commercial reach with our differentiated rehabilitation technologies,&#8221; added Gary Sagiv, CEO of Motion Informatics. 
On Monday, ReShape Lifesciences announced 2024 revenue of $8 million, a contraction of 7.7%, or $700,000, compared <a href="https://www.benzinga.com/pressreleases/25/04/g44673681/reshape-lifesciences-reports-year-ended-december-31-2024-financial-results-and-provides-corporate-" target="_blank" rel="noreferrer noopener">to the same period in 2023</a>.
The primary reason for the decrease is due to the introduction of GLP-1 pharmaceuticals within the U.S.
With the introduction of Lap-Band 2.0, the company experienced a slight growth in units sold of 6.5%.
However, sales of the Lap-Band accessories units decreased by 26.4% within the U.S.
Worldwide sales of Lap-Band units decreased by 8.5%, and accessories decreased by 25.9%. The company increased the price of Lap-Band systems, including accessories, which helped revenues not decrease at the same ratio as the decline in unit sales.
Price Action: ReShapestock is up 80.1% at $0.62 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44725000/kkr-outbids-competitors-edges-closer-to-29b-karo-healthcare-takeover-report" target="_blank" rel="noreferrer noopener">KKR Outbids Competitors To Secure $2.9 Billion Karo Healthcare Takeover</a></li>
</ul>
Image: Shutterstock

Penny Stocks

Health Care

General

RSLS

Penny Stock ReShape To Distribute FDA-Cleared Neuromuscular Device In US

Government

Regulations

Politics

White House's Miran Says Need To Get Regulations Out Of The Way So That Companies Can Build Factories Faster; President Trump's Policies Are Working At Keeping Inflation At Bay

Canaccord Genuity analyst Austin Moeller maintains Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) with a Buy and raises the price target from $14.5 to $15.5.

SPIR

Canaccord Genuity Maintains Buy on Spire Global, Raises Price Target to $15.5

Canaccord Genuity analyst Kyle Mikson maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Buy and maintains $3 price target.

PACB

Canaccord Genuity Maintains Buy on Pacific Biosciences, Maintains $3 Price Target

JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Market Outperform and maintains $78 price target.

CYTK

JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target

As of April 10, 2025, two stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Wheeler Real Estate Investment Trust Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)</h3>
<ul>
<li>On March 4, Wheeler Real Estate IT posted fourth-quarter FFO of $18.48, down from $182.82 in the year-ago period. The company's sales rose to $27.59 million from $26.21 million. The company has a 52-week high of $3,588.00.</li>
<li>RSI Value: 70.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>WHLR Price Action: Shares of Wheeler Real Estate Investment Trust fell 4.8% to close at $2.37 on Wednesday.</li>
<li>Edge Stock Ratings: 0.39 Momentum score with Value at 36.37. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/whlr"><img loading="lazy" decoding="async" width="487" height="188" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10044415/image-62.png" alt="" class="wp-image-865450" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10044415/image-62.png 487w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10044415/image-62-300x116.png 300w" sizes="(max-width: 487px) 100vw, 487px" /></a></figure>
<h3 class="wp-block-heading">Stratus Properties Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRS#NASDAQ">STRS</a>)</h3>
<ul>
<li>On March 28, the company said revenues for 2024 surged to $54.2 million from $17.3 million for 2023. William H. Armstrong III, Chairman of the Board of Directors (Board) and Chief Executive Officer of Stratus, stated, &#8220;Our experienced team continues to successfully execute on our disciplined strategy by delivering on value-enhancing transactions, continuing to advance our development projects and returning capital to stockholders." The company's stock gained around 23% over the past five days and <a href="https://www.benzinga.com/quote/STRS">has a 52-week high</a> of $30.66.</li>
<li>RSI Value: 75.4</li>
<li>STRS Price Action: Shares of Stratus Properties gained 18.1% to close at $20.91 on Wednesday. </li>
</ul>
How do other stocks rank? Get the full <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">BZ Edge Rankings breakdown here</a>.
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

STRS

WHLR

Top 2 Real Estate Stocks That May Keep You Up At Night This Month

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo raised Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) price target from $30 to $39. Wells Fargo analyst Jeff Cantwell upgraded the rating from Underweight to Overweight. Toast shares closed at $34.38 on Wednesday. <a href="https://www.benzinga.com/quote/TOST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim slashed the price target for Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) from $15 to $13. Guggenheim analyst Subbu Nambi maintained a Buy rating. Neogen shares closed at $5.02 on Wednesday. <a href="https://www.benzinga.com/quote/NEOG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS lowered BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) price target from $38 to $31. UBS analyst Joseph Spak downgraded the stock from Buy to Neutral. BorgWarner shares closed at $26.89 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/BWA/analyst-ratings">view this stock</a>.</li>
<li>Truist Securities cut the price target for IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) from $263 to $216. Truist Securities analyst Jailendra Singh maintained a Buy rating. IQVIA shares closed at $157.02 on Wednesday. <a href="https://www.benzinga.com/quote/IQV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from $171 to $159. B of A Securities analyst Tim Anderson maintained a Neutral rating. Johnson &amp; Johnson shares closed at $150.97 on Wednesday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital slashed Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) price target from $275 to $170. Loop Capital analyst Mark Schappel downgraded the stock from Buy to Hold. Manhattan Associates shares settled at $166.26 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view </a><a href="https://www.benzinga.com/quote/MANH/analyst-ratings">this </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">stock</a>.</li>
<li>Barclays cut ManpowerGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) price target from $55 to $50. Barclays analyst Manav Patnaik upgraded the stock from Underweight to Equal-Weight. ManpowerGroup shares closed at $52.87 on Wednesday. <a href="https://www.benzinga.com/quote/MAN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities slashed Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) price target from $265 to $230. Truist Securities analyst Youssef Squali maintained a Buy rating. Amazon shares closed at $191.10 on Wednesday.  <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho cut the price target for NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from $4.2 to $3.5. Mizuho analyst Vijay Rakesh maintained a Neutral rating. NIO shares settled at $3.31 on Wednesday. <a href="https://www.benzinga.com/quote/NIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler slashed Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) price target from $208 to $185. Piper Sandler analyst Thomas Champion maintained an Overweight rating. Alphabet shares closed at $158.71 on Wednesday. <a href="https://www.benzinga.com/quote/googl/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying GOOGL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-1024x577.png" alt="" class="wp-image-865996" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10092133/image-69.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

AMZN

MANH

NEOG

TOST

Alphabet To $185? Here Are 10 Top Analyst Forecasts For Thursday

Contracts

SYNX

Silynxcom Secures New Purchase Order Valued At ~$1.13M From The Israel Defense Forces

Scotiabank analyst Greg McGinniss maintains Americold Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COLD#NYSE">COLD</a>) with a Sector Outperform and lowers the price target from $28 to $24.

COLD

Scotiabank Maintains Sector Outperform on Americold Realty Trust, Lowers Price Target to $24

Macro Economic Events

Economics

White House Economic Adviser Miran Says President Is Buying Time To Create Trade Deals; Never Thought That We Were Headed For Meaningful Recession; Need To Get Regulations Out Of The Way So That Companies Can Build Factories Faster

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the utilities sector.
<h3 class="wp-block-heading">The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>)</h3>
<ul>
<li>Dividend Yield: 6.28%</li>
<li>Mizuho analyst Anthony Crowdell maintained an Outperform rating and cut the price target from $16 to $15 on March 4, 2025. This analyst has an accuracy rate of 64%.</li>
<li>B of A Securities analyst Julien Dumoulin-Smith upgraded the stock from Underperform to Neutral and raised the price target from $11 to $13 on March 4, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: The AES will host a conference call on Friday, May 2, to review its first quarter financial results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">latest AES news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="908" height="801" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045908/image-63.png" alt="" class="wp-image-865471" style="width:514px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045908/image-63.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045908/image-63-300x265.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045908/image-63-768x677.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Avista Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVA#NYSE">AVA</a>)</h3>
<ul>
<li>Dividend Yield: 4.94%</li>
<li>Jefferies analyst Julien Dumoulin-Smith maintained a Hold rating and slashed the price target from $40 to $39 on Jan. 28, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Mizuho analyst Anthony Crowdell upgraded the stock from Underperform to Neutral and raised the price target from $32 to $36 on May 3, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Recent News: Avista will hold its quarterly conference call and webcast to discuss first quarter results on Wednesday, May 7.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest AVA <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="911" height="812" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045936/image-64.png" alt="" class="wp-image-865473" style="width:599px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045936/image-64.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045936/image-64-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10045936/image-64-768x685.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">Northwest Natural Holding Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>)</h3>
<ul>
<li>Dividend Yield: 4.85%</li>
<li>Stifel analyst Selman Akyol maintained a Buy rating and cut the price target from $45 to $44 on Nov. 14, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Janney Montgomery Scott analyst Michael Gaugler upgraded the stock from Neutral to Buy and raised the price target from $36 to $43 on Aug. 5, 2024. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On March 3, NW Natural Holdings named Justin B. Palfreyman as new CEO.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest NWN <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="915" height="823" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10050011/image-65.png" alt="" class="wp-image-865476" style="width:495px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10050011/image-65.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10050011/image-65-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10050011/image-65-768x691.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Dividends

Wall Street's Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and raises the price target from $18 to $20.

BNTC

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $20

ISRG

Intuitive Says FDA Clears Fully Wristed SP SureForm 45 Stapler Designed For Single-Port Robotic Surgery

WIIM

Viking Holdings shares are trading lower. Morgan Stanley cut its price target on the stock from $49 to $47.

Home furnishing brand The Lovesac Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) shares are <a href="https://www.benzinga.com/premarket">surging in premarket on Thursday</a>, after the fourth-quarter earnings.
The company reported a <a href="https://www.benzinga.com/pressreleases/25/04/g44730835/the-lovesac-company-reports-fourth-quarter-and-fiscal-2025-financial-results">fourth-quarter FY25 revenue decline </a>of 3.6% year-on-year to $241.490 million, beating the analyst consensus estimate of $233.954 million.
Gross profit decreased 2.6% Y/Y to $145.8 million, with the margin expanding 70 basis points to 60.4%. Total comparable sales declined 9.4%. Internet sales dropped 9.7% in the quarter.
Total operating expenses fell 10.1% Y/Y to $98.2 million. The operating income increased 17.8% to $47.6 million and the operating margin expanded 360 basis points to 19.7%.
Also Read: <a href="https://www.benzinga.com/news/25/04/44698868/tariffs-recession-fears-could-derail-wayfair-rh-and-etsy-says-analyst">Tariffs, Recession Fears Could Derail Wayfair, RH And Etsy, Says Analyst</a>
Adjusted EBITDA increased 11.4% Y/Y to $53.9 million. EPS of $2.13&nbsp;<a href="https://www.benzinga.com/earnings">topped the consensus </a>of $1.87.
As of July 30, 2023, Lovesac held $54.7 million in cash and equivalents. Net cash provided by operating activities during the quarter totaled $44 million.
&#8220;After a slow start to the holiday selling season, strong execution by our teams dramatically improved conversion of customer quotes to sales throughout the remainder of the fourth quarter. This supported a mid-teens year-over-year increase in net income for the quarter and helped close out another year of market share gains for full year Fiscal 2025,&#8221; said CEO Shawn Nelson.
Lovesac appointed Heidi Cooley as <a href="https://www.benzinga.com/pressreleases/25/04/g44730896/the-lovesac-company-appoints-heidi-cooley-as-chief-brand-and-marketing-officer">Chief Brand and Marketing Officer</a>, effective April 23, 2025. 
Outlook: For the first quarter Lovesac sees EPS of $(0.66) &#8211; $(0.85) versus the Street view of $(0.77) and sales of $136 million &#8211; $142 million against the estimate of $138.60 million.
The company expects FY26 EPS of $0.80 &#8211; $1.36 versus the estimate of $1.10 and sales of $700 million &#8211; $750 million versus the estimate of $713.05 million.
Price Action: LOVE shares traded higher by 16.38% at $18.54 in premarket at last check Thursday.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44703031/this-beverage-maker-tobacco-company-and-packaged-food-giant-outshine-in-a-recession">This Beverage Maker, Tobacco Company And Packaged Food Giant Outshine In A Recession</a>
Photo: Shutterstock

LOVE

Why Is Home Furnishing Brand Lovesac's Stock Surging Today?

BRTX

BioRestorative Therapies Confirms It Faces No Material Impact From Reciprocal Tariffs

NextNRG, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXXT#NASDAQ">NXXT</a>), a pioneer in AI-driven energy innovation—transforming how energy is produced, managed, and delivered through its advanced Utility Operating System, smart microgrid technology, wireless EV charging, and on-demand mobile fuel delivery solutions— today announced preliminary unaudited revenue and volume results for March 2025 and the first quarter of 2025. The company delivered its third consecutive record month, with March revenue increasing 161% year-over-year to approximately $6.15 million.
March 2025 Highlights
<ul>
<li>Revenue: $6,148,266 (vs. $2,354,048 in March 2024)</li>
<li>YoY Revenue Growth: 161%</li>
<li>Gallons Delivered: 1,799,955 (vs. 580,217 in March 2024)</li>
<li>YoY Gallon Growth: 210%</li>
</ul>
Q1 2025 Highlights
<ul>
<li>Revenue: $16,232,354 (vs. $6,597,119 in Q1 2024)</li>
<li>YoY Revenue Growth: 146%</li>
<li>Gallons Delivered: 4,688,045 (vs. 1,658,272 in Q1 2024)</li>
<li>YoY Gallon Growth: 183%</li>
</ul>

Earnings

Guidance

NXXT

NextNRG Reports Preliminary March 2025 Revenue Of $6,148,266 Up From $2,354,048 YoY; Q1 Revenue $16,232,354 Up From $6,597,119 YoY

Press Releases

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Comments

Mineralys Therapeutics

Mineralys Therapeutics (MLYS) Opciones

Mineralys Therapeutics (NASDAQ:MLYS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL